Reice Kerr

Laboratory Scientist at NexaBiome

Reice Kerr is a Laboratory Scientist at NexaBiome since June 2023, previously serving as a Research Associate and Industrial Placement Student at OCEANIUM from June 2021 to May 2023. Kerr's early career includes roles as a Receptionist at Glasgow Life from April 2017 to October 2021 and a Summer Intern at Manipal Institute of Technology in July 2019, where experience included working in a Biotechnology and Plant Science Laboratory. Educational qualifications include a Master of Science in Industrial Biotechnology from the University of Strathclyde and a Bachelor of Science in Microbiology from the University of Glasgow. Early work experience also includes a position as a Crew Member at McDonald's from August 2014 to December 2016.

Location

Glasgow, United Kingdom

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


NexaBiome

NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.


Employees

11-50

Links